Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
Open accessThe DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM) is the second most common hematological malignancy, characterized by an abnormal accumulation of plasma cells in the bone marrow. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of multiple genes to regulate various principal biological functions, for example, cell proliferation and survival, stemness, inflammation and immune responses. Aberrant STAT3 activation has been identified as a key driver of tumorigenesis in many types of cancers, including MM. Herein, we summarize the current evidence for the role of STAT3 in affecting cancer hallmark traits by: (1) sustaining MM cell survival and proliferation, (2) regulating tumor microenvironment, (3) inducing immunosuppression. We also provide an update of different strategies for targeting STAT3 in MM with special emphasis on JAK inhibitors that are currently undergoing clinical trials. Finally, we discuss the challenges and future direction of understanding STAT3 signaling in MM biology and the clinical development of STAT3 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Venn diagrams of genes upregulated in MM cell lines after additional IL-6 stimulation. The MM-STAT3 signature contains 15 upregulated genes shared by studies of Brocke-Heidrich K, et al. (B-H.K., ref. [21]) and Tsuyama N (T.N., ref. [22]).](https://figures.cochat.ai/paper-figures/8edacda888dd49b5bd9c7340f3dca7c6/biological-hallmarks-and-emerging-strategies-to-target-stat3-signaling-in-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the abnormal activation of the JAK/STAT pathway has been identified as a key factor driving the development of MM [107].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 2×
“In their updated model, Hanahan and Weinberg proposed eight “hallmarks of cancer” that all malignancies must achieve, including sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, reprogrammin…”
BackgroundMethodDarnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“Janus tyrosine kinases (JAKs)-STAT pathway was originally discovered in the context of interleukin-mediated inflammatory response [15].”
BackgroundKumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177 · cited 1×
“Multiple myeloma (MM) is a plasma cell neoplasm that results from the clonal expansion of an immunoglobulin-secreting terminally differentiated B cell [1].”
BackgroundDiagnosis and Management of Multiple Myeloma: A Review
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L. A., Tuazon, S., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,029 · cited 1×
“However, MM remains an incurable disease with a five-year survival rate of around 54% [7].”
BackgroundWidespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988 · cited 1×
“The challenges in treating MM partially arise from the remarkable heterogeneity in the genetic and epigenetic abnormalities of this disease [8,9].”
Backgroundvan de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
A Phosphatase Associated with Metastasis of Colorectal Cancer
Saha, S., Bardelli, A., Buckhaults, P., Velculescu, V. E., Rago, C., Croix, B. S., Romans, K. E., Choti, M. A., Lengauer, C., Kinzler, K. W., et al. (2001) · Science · doi:10.1126/science.1065817 · Cited by 648 · cited 2×
“Bert Vogelstein’s group first identified that PRL-3 was overexpressed in metastatic colorectal cancer [28].”
BackgroundIMWG consensus on risk stratification in multiple myeloma
Chng, W. J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N., Palumbo, A., Miguel, J. S., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2013.247 · Cited by 601 · cited 2×
“PRL-3 is overexpressed in MGUS, SMM, and MM, compared to PCs from healthy persons.”
BackgroundSelf-citationHyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464 · cited 4×
“The innate immune system serves as the first line of defense that consists of natural killer (NK) cells, mast cells, eosinophils, basophils, macrophages, neutrophils, dendritic cells (DCs) and humoral factors (cytokines and complement).”
BackgroundInfluentialBroyl, A., Hose, D., Lokhorst, H., de Knegt, Y., Peeters, J., Jauch, A., Bertsch, U., Buijs, A., Stevens-Kroef, M., Beverloo, H. B., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261032 · Cited by 329
Cited by
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Guan, X., Yang, J., Wang, W., Zhao, B., Hu, S., Yu, D., Yuan, L., Shi, Y., Xu, J., Dong, J., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106703 · Cited by 33
Alimohammadi, M., Rahimzadeh, P., Khorrami, R., Bonyadi, M., Daneshi, S., Nabavi, N., Raesi, R., Farani, M. R., Dehkhoda, F., Taheriazam, A., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155401 · Cited by 29
Zhang, C., Zhao, Y., Wang, Q., Qin, J., Ye, B., Xu, C., & Yu, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158661 · Cited by 16
Cancer Biology and Therapeutics: Navigating Recent Advances and Charting Future Directions
Cleanclay, W. D., Zakari, S., Adigun, T. O., Ayeni, T. O., Nnaji, P. C., Amuji, D. N., Blessing, A., Adebosoye, A., Gbadebo, M., Agbetuyi-Tayo, P., et al. (2023) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v7i12.4 · Cited by 21
Antisense oligonucleotides-based approaches for the treatment of multiple myeloma
Oprea, M., & Ionita, M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139186 · Cited by 16
Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes
Uckun, F. M., & Qazi, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129943 · Cited by 11
Li, H., Zhu, X., Sun, Z., Wang, Q., Song, S., Xu, Y., He, G., & Mao, X. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00222 · Cited by 6
Xu, M. X., Liu, X., Zhang, H., Xu, H., Ma, X., Yang, Y., Duan, C., Tang, S., Liu, Y., Li, C., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70071 · Cited by 4
“Therefore, targeting STAT3 presents a promising strategy for developing new anti-MM drugs (Chong, Chng, & de Mel, 2019; Zhou & Chng, 2022).”
Biological research on the occurrence and development of multiple myeloma and its treatment
Wu, Y., Shi, X., Yao, X., & Du, X. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.850 · Cited by 5
“Exosomes derived from MM cells can increase the phosphorylation level of Signal transducers and activators of transcription 3 (STAT3) and up‐regulate antiapoptotic protein B‐cell lymphoma.(23) The expression of BCL‐XL and myeloid cell leukemia I (MCL‐ I) can activate myeloid‐derived suppressor cells (MDSC), enhance it…”
BackgroundXu, Y., & Mao, J. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101633 · Cited by 1
Shivali, Kumar, H., & Agnihotri, N. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106928 · Cited by 3
A Bird’s Eye View: A Close Look into Avian CAM Models for Translational Blood Cancer Research
Cymer, I., McAuley, N., Richards, C. E., Jahns, H., Glavey, S. V., & Hopkins, A. M. (2026) · Cancers · doi:10.3390/cancers18020209 · Cited by 1
“Unlike solid tumours, which often induce angiogenesis to sustain growth within a localised area [10,13], the dispersal of blood cancer through haematopoietic and lymphatic cells makes it difficult to follow disease progression and to isolate specific microenvironmental causative factors [14].”
STAT3 inhibition eradicates multiple myeloma stem-like cells and induces immunogenic cell death
Sha, Y., Li, W., Zhang, Y., Liu, T., Yuan, M., Wang, W., Gu, J., Cheng, H., Niu, M., Yang, P., et al. (2026) · Blood Science · doi:10.1097/bs9.0000000000000301 · Cited by 1
Vitamin D, inflammation, and cancer
Kállay, E., Schepelmann, M., & Buburuzan, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91338-6.00037-9
Mutra, R., Mundodan, F., Vallem, A., Lawrie, C. H., Solé, C., Panizo, C., Ghatage, P., Anciya, V. R., & Vallabhapurapu, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.29.675399
“Among the known oncogenic pathways in MM, the Jak-STAT pathway driven especially by IL-6 to activate STAT3 plays key roles in MM cell survival and cancer progression (19, 24-31).”
Li, H., Chen, Y., Gregorová, M., Yang, T., Zhang, X., Yu, X., Wang, Z., Hua, H., Ye, L., Qi, X., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101242
Dissecting the role of long non-coding RNA in multiple myeloma
Zocchi, S. (2024) · theses.fr (ABES) · doi:10.70675/22f35f26z6442z47d6z8cdaz153527b5df6e
Faruq, O., Iyer, D. N., Wang, P., Shrestha, M., Wei, C., Schimmer, A. D., & Chang, H. (2026) · British Journal of Haematology · doi:10.1111/bjh.70736
STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma
Kepp, O., & Kroemer, G. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2732727
Wen, J., Zhou, Q., Yue, J., Zhang, Y., Zheng, Y., & Xu, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1815669
“Abnormal activation of the JAK/STAT pathway has been identi fi ed as a key driver in MM progression (162).”
Műzes, G., & Sípos, F. (2026) · Biomedicines · doi:10.3390/biomedicines14102288
“Constitutive or sustained STAT3 activation enhances anti-apoptotic signaling and has been implicated in the persistence and progression of malignant plasma-cell populations [38–40].”
Metadata
- Authors
- Zhou, J., & Chng, W.-J.
- Affiliations
- National University of Singapore (SG)
- Corresponding author
- Zhou, Jianbiao
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 11
- Issue
- 6
- Pages
- 941
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC8946161
- OpenAlex
- W4220897706
- Semantic Scholar
- 35302bba7072be204b2a89ad7b2ecd88623ab85c
- Cited by
- 22
- References
- 74
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 1
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation
- National University of Singapore
- National Research Foundation Singapore
- National Medical Research Council (CIRG19nov-0006)
- Institute for Health Innovation and Technology, National University of Singapore
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- multiple myeloma, STAT3 signaling, cancer hallmarks, tumor microenvironment, immunosuppression, JAK inhibitors, STAT3 inhibitor, clinical trials, plasma cells
- MeSH terms
- Antineoplastic Agents, Humans, Multiple Myeloma, Signal Transduction, STAT3 Transcription Factor, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.